Phase 1Completed
Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease
A Phase, I Prospective, Randomized, Double-Blinded, Placebo-controlled, Trial to Evaluate the Safety and Potential Efficacy of Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease
- Sponsor
- Longeveron Inc. (Industry)
- Enrolment
- 33 enrolled
- Conditions
- Alzheimer's Disease
- Interventions
- Longeveron Mesenchymal Stem Cells; Placebo
- Ages
- adults, older adults
- Registry
- NCT02600130
From the registry
This is a Phase I, prospective, randomized, placebo-controlled, double-blinded study designed to test the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) for the treatment of subjects with clinically diagnosed Alzheimer's disease.
Primary outcomes
- To demonstrate the safety of LMSCs administered to subjects with Alzheimer's disease.